Microbot Medical Confirms Uninterrupted Operations, Expands Team and Inventory for LIBERTY April Launch
Microbot Medical’s U.S. and Israeli operations, manufacturing partner and distribution remain fully functional despite geopolitical tensions, with employee safety ensured. Following FDA clearance, the company is building LIBERTY system inventory, expanding its U.S. commercial team and HEOR leadership ahead of April launch at the Society of Interventional Radiology meeting.
1. Operational Stability
Microbot Medical reports uninterrupted operations in both U.S. and Israeli facilities, with its manufacturing partner fully functional and employee safety prioritized despite regional geopolitical tensions.
2. Commercial Infrastructure Build-out
Following FDA clearance of the LIBERTY Endovascular Robotic System, the company has secured sufficient U.S. inventory, is increasing stock via a third-party logistics provider, and has hired additional sales representatives and a Director of Health Economics and Outcomes Research to strengthen its U.S. commercial team.
3. April SIR Full Release Preparation
The company is preparing for a full market launch of LIBERTY at the Society of Interventional Radiology meeting in April 2026, aiming to deepen market adoption through demonstrations and expanded U.S. territory coverage.